TOPIK Study: A Study to Report Progressive Multifocal Leukoencephalopathy and Other Serious Opportunistic Infections in Natalizumab Treated Participants

NCT05236777 · clinicaltrials.gov ↗

COMPLETED

Status

675

Enrollment

INDUSTRY

Sponsor class

Conditions

Multiple Sclerosis

Interventions

DRUG: Natalizumab

Sponsor

Biogen

Collaborators

[object Object]